VIREXX MEDICAL
ViRexx Medical provides treatment of cancer and chronic viral infections.
VIREXX MEDICAL
Industry:
Biotechnology Health Care
Address:
Edmonton, Alberta, Canada
Country:
Canada
Website Url:
http://www.virexx.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF LetsEncrypt Nginx DoubleClick.Net CloudFront Google Adsense AdBlock Acceptable Ads Google Adsense For Domains
Similar Organizations
AbViser Medical LLC
AbViser Medical LLC provides healthcare products for critical care and surgical marketplaces.
Cogentix Medical
Cogentix Medical products have increased treatment efficiency and lowered patient risk.
DZZOM
DZZOM is provides targeted drug bio marker R&D cost and time efficient.
FABtec Medical
FABtec Medical focuses on the endoscopic treatment of morbid obesity and metabolic illness.
Kcancer
Kcancer provides information on cancer and other chronic diseases.
Pain Consultants of Arizona
Pain Consultants of Arizona provides treatment of acute and chronic painful conditions.
Preffered Global Health
Preffered Global Health is a global patient organization with treatment programs for cancer & critical illness.
The Institute for Health Promotion Research (IHPR)
The Institute for Health Promotion Research provides solutions to impacts of cancers, chronic diseases, and obesity.
Zero2One Diagnostics
Clinical treatment of bacterial infections
Official Site Inspections
http://www.virexx.com
- Host name: 104.247.81.52
- IP address: 104.247.81.52
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "ViRexx Medical"
ViRexx Medical - Crunchbase Company Profile & Funding
ViRexx Medical provides treatment of cancer and chronic viral infections. on Nov 7, 2008. Where is ViRexx Medical's headquarters? ViRexx Medical is located in Edmonton, Alberta, Canada. …See details»
ViRexx Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, investors, and executives for ViRexx. Use the PitchBook Platform to explore the full profile.See details»
ViRexx Medical Corp. Is Acquired by Paladin Labs Inc.
ViRexx is a Canadian-based development-stage biotech company focused on developing innovative-targeted therapeutic products that offer better quality of life and a renewed hope for …See details»
Virexx Medical Corp. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Virexx Medical Corp. of Edmonton, AB. Get the latest business insights from Dun & Bradstreet.See details»
Paladin acquires early-stage biotech, vax platform
Dec 23, 2008 · Former ViRexx shareholders could receive up to $2.5 million if certain conditions are met within the next week, Paladin Labs has completed its acquisition of ViRexx Medical …See details»
Virexx Medical Corp - Company Profile and News - Bloomberg …
ViRexx Medical Corp is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and chronic viral infections. ViRexx's most …See details»
Paladin completes acquisition of ViRexx - The Toronto Star
Dec 23, 2008 · EDMONTON–Paladin Labs Inc. has completed the acquisition of ViRexx Medical Corp. (TSX: VIR), a bankrupt biotechnology company with several promising technologies …See details»
ViRexx Medical Corp. - VentureRadar
Find out more about ViRexx Medical Corp. including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
ViRexx Medical - Tech Stack, Apps, Patents & Trademarks
ViRexx Medical provides treatment of cancer and chronic viral infections.See details»
ViRexx Medical - Crunchbase
ViRexx Medical provides treatment of cancer and chronic viral infections.See details»
Virexx Medical Corp. – ASTech Awards
Virexx Medical Corp. has developed a novel technology, Chimigen™ platform, for application in vaccines to treat chronic infectious diseases such as hepatitis B and hepatitis C. In a healthy …See details»
Arie Laor | CEO at Virexx | F6S Member Profile
View Arie Laor's profile on F6S - Virexx - Serial entrepreneur MSc in Physics, founded managed start-up companies 12y in biotech self education in molecular biology, and otherSee details»
ViRexx Enters Agreement To Buy Familiar Firm: AltaRex
Oct 18, 2004 · ViRexx's shares (TSX:VIR) fell C3 cents to close at C$1.07. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology …See details»
Canadian Organizations to Investigate ViRexx’ Vaccine Platform …
The National Institute of Nanotechnology and Defence Research and Development Canada will study the Chimigen™ Vaccine platform. ViRexx Medical inked deals with the Canada’s …See details»
Oregovomab | Drugs in R&D - Springer
Oct 23, 2012 · ViRexx Medical Corp is developing the murine monoclonal antibody oregovomab [OvaRex®, MAb B43.13] for the treatment of ovarian cancer. Oregovomab targets the …See details»
ViRexx Announces Collaboration With the National Institute of ...
ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral …See details»
ViRexx Medical Corp (VIR) Stock Message Board | InvestorsHub
May 30, 2007 · ViRexx Medical Corp. is an Edmonton, Alberta-based biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and …See details»
ViRexx Medical Corp. Announces Change in Management and
EDMONTON, ALBERTA--(CCNMatthews - May 3, 2007) - ViRexx Medical Corp. (“ViRexx”) (TSX:VIR) (AMEX:REX), announces that Dr. D. Lorne Tyrrell has resigned as Chief Executive …See details»
Solid tumour therapies(ViRexx) - Drug Targets, Indications
AltaRex (now ViRexx Medical Corp) has established several strategic corporate alliances for the development and/or commercialisation of oregovomab. Unither Pharmaceuticals, a subsidiary …See details»
Oregovomab: Anti-CA-125 Monoclonal Antibody B43.13
Jan 1, 2006 · ViRexx Medical Corp is developing the murine monoclonal antibody oregovomab [OvaRex®, MAb B43.13] for the treatment of ovarian cancer.See details»